A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System

被引：0
|
作者：
Altman, Keith [1 ]
Budny, Renata [2 ]
机构：
[1] Law Off Keith Altman, Massapequa Pk, NY USA
[2] New York City Coll Technol, Brooklyn, NY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
744
引用
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [31] Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system
    Wang, Xiaomeng
    Wang, Jimei
    Liu, Fang
    Zhang, Kexin
    Zhao, Min
    Xu, Lin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [32] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    Drug Safety, 2012, 35 : 507 - 518
  • [33] Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
    Pan, Xianglin
    Xiao, Xiangtian
    Ding, Yiling
    Shu, Yamin
    Zhang, Wenting
    Huang, Liu
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
    Li, Liangxia
    Xu, Qianqian
    Liu, Yarui
    Pang, Liangfang
    Cui, Zhou
    Lu, Yuanyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
    Wu, Fan
    Zhu, He
    Zhang, Yue
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [37] Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System
    Zhao, Dehua
    Long, Xiaoqing
    Wang, Jisheng
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 599 - 605
  • [38] Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
    Gatti, Milo
    Fusaroli, Michele
    Raschi, Emanuel
    Moretti, Ugo
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) : 1421 - 1431
  • [39] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [40] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345